[ad_1]
Dublin, December 31, 2021 /PRNewswire/– “Investigation Report” China’s Metformin market 2021-2025″ Report has been added to ResearchAndMarkets.com supply.
Analysts predict that with the relief of COVID-19, sales of metformin in the Chinese market will show a recovery growth from 2021 to 2025.
According to analysts’ market research, sales of metformin in the Chinese market have increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall medical diagnosis and treatment services, the sales of metformin in the Chinese market will fall to 707 million yuan In 2020, it was down 4.19% year-on-year. The CAGR of metformin sales in the Chinese market from 2016 to 2020 is 7.01%.
Metformin is the first-line treatment for type 2 diabetes, especially for overweight people. Metformin was originally developed by Merck Sharp & Dohme (trade name: GLUCOPHAGE).
GLUCOPHAGE was first listed on France Listed in 1957 and China After 1994, some generic drugs have also been listed on the Chinese market one after another.According to analyst’s market research, there are several manufacturers in China’s In the metformin market by 2020, China-US Shanghai Squibb Pharmaceuticals Co., Ltd. has the largest market share.
In addition, the number of diabetic patients China Ranked first in the world. The overall prevalence of adult diabetes is 12.8%. Type II diabetes accounts for 90% of diabetic patients, and the number of patients is huge. exist…
The full story can be found on Benzinga.com
[ad_2]
Source link
